The use of 2L interventions targeting the PD-L1/PD-1 axis, such as avelumab,pembrolizumab, spartalizumab, nivolumab and toripalimab, in EP-PD-NEC is underinvestigation in multiple ongoing clinical trials (Table 4). The gene discussed is CD274; the disease is neuroendocrine carcinoma.